A disintegrin and metalloproteinase 22 activates integrin β1 through its disintegrin domain to promote the progression of pituitary adenoma

Abstract excerpt

BACKGROUND: Approximately 35% of pituitary adenoma (PA) display an aggressive profile, resulting in low surgical total resection rates, high recurrence rates, and worse prognosis. However, the molecular mechanism of PA invasion remains poorly understood. Although "a disintegrin and metalloproteinases" (ADAMs) are associated with the progression of many tumors, there are no reports on ADAM22 in PA. METHODS: PA...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to HER2/EGFR in Cancer Research
• Share to Meningioma and schwannoma management
• Share to Pituitary Gland Disorders and Treatments